Though midostaurin has not been found to be effective in combination with intensive chemotherapy for FLT3-wildtype disease [180], the results from the phase II QUIWI study suggested improved survival in patients with FLT3-wildtype AML undergoing intensive induction who were randomized to quizartinib over a placebo [181]. Here, FLT3 is linked to acute myeloid leukemia.